Use of the Sustained Pain-Free Plus No Adverse Events Endpoint in Clinical Trials of Triptans in Acute Migraine
Authors:
- 1 January 2007
- journal article
- research article
- Published by Springer Nature in CNS Drugs
- Vol. 21 (1) , 73-82
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Review of clinical trials using early acute intervention with oral triptans for migraine managementInternational Journal Of Clinical Practice, 2006
- Focus on trial endpoints of clinical relevance and the use of almotriptan for the acute treatment of migraineInternational Journal Of Clinical Practice, 2005
- Consensus Statement: Cardiovascular Safety Profile of Triptans (5‐HT1B/1D Agonists) in the Acute Treatment of MigraineHeadache: The Journal of Head and Face Pain, 2004
- Defeating migraine pain with triptans: A race against the development of cutaneous allodyniaAnnals of Neurology, 2003
- Tolerability of the TriptansDrug Safety, 2003
- A Long‐term Open‐Label Study of Oral Almotriptan 12.5 mg for the Treatment of Acute MigraineHeadache: The Journal of Head and Face Pain, 2002
- Preference Comparison of Rizatriptan ODT 10‐mg and Sumatriptan 50‐mg Tablet in MigraineHeadache: The Journal of Head and Face Pain, 2001
- Quality of Life Assessment Among Migraine Patients Treated With SumatriptanHeadache: The Journal of Head and Face Pain, 1995
- Migraine Symptoms: Results of a Survey of Self‐Reported MigraineursHeadache: The Journal of Head and Face Pain, 1995
- The Burden of MigrainePharmacoEconomics, 1994